Given that the binding of CD47 with SIRPα in tumor cells limits the anti-cancer immune response, it is possible that therapies that inhibit CD47 signaling in cancer cells would promote the phagocytosis of tumor cells by macrophages and thereby limit tumor growth (11). This evidence concerns the gene CD47 and cancer.